Revisiting mouse minute virus inactivation by high temperature short time treatment
Autor: | Robert Kiss, Jacob Hoffman, Paul W. Barone, Joleen Su, Houman Dehghani, Shelley Alvarado, Jonathan Rice, Martina Kopp, Marie Murphy, Mark Bailey, Stacy L. Springs, Michael E. Wiebe, Dayue Chen |
---|---|
Rok vydání: | 2021 |
Předmět: |
0106 biological sciences
0301 basic medicine Hot Temperature Time Factors Inactivation kinetics Industry standard Bioengineering Biology 01 natural sciences Applied Microbiology and Biotechnology Mice 03 medical and health sciences 010608 biotechnology Animals Humans Cell Line Transformed Log reduction business.industry Potential risk Hold time Contamination Biotechnology Mouse minute virus 030104 developmental biology Minute Virus of Mice Virus Inactivation business Viral contamination |
Zdroj: | Biotechnology and Bioengineering. 118:2967-2976 |
ISSN: | 1097-0290 0006-3592 |
Popis: | In recent years, high temperature short time (HTST) treatment technology has been increasingly adopted for medium treatment to mitigate the potential risk of viral contamination in mammalian cell culture GMP manufacturing facilities. Mouse minute virus (MMV), also called minute virus of mice (MVM), implicated in multiple viral contamination events is commonly used as a relevant model virus to assess the effectiveness of HTST treatment of cell culture media. However, results from different studies vary broadly in inactivation kinetics as well as log reduction factors (LRFs) achieved under given treatment conditions. To determine whether the reported discrepancies stemmed from differences in MMV strains, laboratory-scale HTST devices, medium matrices, and/or experimental designs, we have taken a collaborative approach to systematically assess the effectiveness of HTST treatment for MMV inactivation. This effort was conceptualized based on a media treatment gap analysis conducted by the Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB) under the MIT Center for Biomedical Innovation (CBI). Specifically, two different MMV strains were used to evaluate the effectiveness of HTST at various treatment conditions with regard to exposure temperature and hold time duration by two independent laboratories within two different companies. To minimize experimental variations, the two sites used the same batches of MMV stocks, the same commercially purchased medium, and the same model of thermocyclers as the laboratory-scale HTST device. The two independent laboratories yielded similar MMV inactivation kinetics and comparable LRF. No significant differences were observed between the two MMV strains evaluated, suggesting that the variations from prior studies were likely due to differences in equipment, medium matrices, or other factors. The data presented here indicate that MMV inactivation by HTST treatment obeys first-order kinetics and can be mathematically modeled using an Arrhenius equation. The model-based extrapolation provides a quantitative estimate of MMV inactivation by the current industry standard HTST condition (102°C for a hold time of 10 s) used for medium treatment. Finally, based on the data from the current study and the industry experience, it is recommended that any alternative virus barrier technologies adopted for medium treatment should provide a clearance of at least 3.0 LRF based on a worst-case model virus to effectively mitigate potential risks of viral contamination. |
Databáze: | OpenAIRE |
Externí odkaz: |